Hypertension Registry at the Bangkok Hospital Medical Center, Bangkok Thailand: 2-year Experience
Article Sidebar
Main Article Content
Abstract
OBJECTIVES:
The Hypertension Registry at the Bangkok Hospital Medical Center has been working since June 2012. We reported on the first 7 months of 647 registry cases in February 2013. The purpose of this study was to compare and highlight the Registry profile after 2 years in operation. The findings gained from this study are aimed at optimizing service efficiency resulting in better quality of care for patients with hypertension.
MATERIALS AND METHODS: Descriptive analysis using absolute number and percentage was used to draw comparisons between the characteristics of the updated registrants and the registrants from the first 7 months.
RESULTS:
By the end of a 2-year period, the number of active registered cases went up to 3,698 cases compared to 647 cases after the first 7 months of the Registry (December 2012). A total of 1,159 cases were discharged because of lack of follow-up for more than 12 months. Younger registrants, under 21 years of age, took part in the program. The most common associated cardiovascular risk factors included dyslipidemia and diabetes mellitus, and the smoking risk factor has increased significantly. In comparison the history of risk factors and associated diseases at 7 and 24 months from the number of patients have increased. The statistic data of dyslipidemia, diabetes mellitus, heart, kidney diseases, stroke and peripheral vascular disease are not significant changes but in contrast the smoking causes have increased significantly. Angiotensin receptor blocker was still the most commonly used medication in hypertensive care, followed by dihydropyridine calcium channel blocker and beta blocker respectively. Almost half of registrants were successful in achieving blood pressure control.
CONCLUSION:
The Hypertensive Registry at the 2-year point now provides more information beyond individual case treatments. The risk factors of dyslipidemia, diabetes mellitus, cardiovascular, kidney and stroke have not significantly changed in the first 7 months experience study but in contrast, smoking is increasing significantly. These highlights should be emphasized as a strategy of improving care to hypertensive patients.
Article Details
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hyper- tension. J Hypertens 2003;21:1983-92.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62.
5. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Inter- net]. London: Royal College of Physicians (UK); 2011 Aug.
6. Thai Hypertension Society Writing Group. Thai Guide- lines on the treatment of hypertension update 2012. (Accessed January, 2013, at https://www.thaihypertension. org/files/ 216_1.Hypertension_Guideline_2012.pdf.)
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ ESC Guidelines for the management of arterial hyper- tension: the Task Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panelmembers appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-20.
9. Rungtanapirom S, Khankam J, Benjakhunprasit N, et al. Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months’ Experience. Bangkok Med J 2013;5:1-8. (Accessed January 10, 2015 at https://www. bangkokmedjournal.com/sites/default/files/fullpapers/ TBMJ-Vol5-1.pdf).
10. Aekplakorn W, Stolk RP, Neal B, et al. The prevalence and management of diabetes in Thai adults: the inter- national collaborative study of cardiovascular disease in Asia. Diabetes Care 2003;26:2758-63.
11. Buranakitjaroen P1. Hypertension audit in clinical practice based in Thailand (HABIT). J Med Assoc Thai 2011;94:S57-65.
12. Igho-Pemu P, Quarshie A, Oduwole A, et al. Morehouse Community Physicians Network (CPN) hypertension registry:patterns of care and opportunities for targeted medical education. Ethn Dis 2005;15:S5-120-3.
13. Kubozono T, Miyata M, Ueyama K, et al. Clinical signi- ficance and reproducibility of new arterial distensibility index. Circ J 2007;71:89-94.
14. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J 2007;71:1710-4.
15. Okura T, Watanabe S, Kurata M, et al. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 2007;30:335-40.
16. Sakane K, Miyoshi T, Doi M, et al. Association of new arterial stiffness parameter, the cardio-ankle vascular index, withleftventriculardiastolicfunction. JAtheroscler Thromb 2008;15:261-8.
17. Satoh N, Shimatsu A, Kato Y, et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens Res 2008;31:1921-30.
18. Nakamura K, Tomaru T, Yamamura S, et al. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008;72:598-604.
19. Yingchoncharoen T, Limpijankit T, Jongjirasiri S, et al. Arterial stiffness contributes to coronary artery disease risk prediction beyond the traditional risk score (RAMA- EGAT score). Heart Asia 2012;4:77-82.
20. Franklin SS. Arterial stiffness and hypertension: a two- way street? Hypertension 2005;45:349-51.
21. Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000;35:898-903.
22. Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract 2008;62:97-108.
23. Nakamura S, Kawano Y, Inenaga T, et al. Microalbumin- uria and Cardiovascular Events in Elderly Hypertensive Patients without Previous Cardiovascular Complications. Hypertens Res 2003;26:603-8.
24. Mettimano M, Specchia ML, Migneco A, et al. Microal- buminuria as a marker of cardiac damage in essential hypertension. Eur Rev Med Pharmacol Sci 2001;5:31-6.
25. Pontremoli R, Leoncini G, Ravera M, et al. Microalbu- minuria, cardiovascular, and renal risk in primary hyper- tension. J Am Soc Nephrol 2002;13:S169-72.
26. Palatini P. Microalbuminuria in hypertension. Curr Hypertens Rep 2003;5:208-14.
27. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in HypertensivePatients with Left Ventricular Hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6.
28. Viazzi F, Leoncini G, Conti N, et al. Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study. Clin J Am Soc Nephrol 2010;5:1099-106.
29. S Jalal, FA Sofi, MS Alai, et al. Prevalence of microalbu- minuria in essential hypertension: A study of patients with mild to moderate hypertension. Indian J Nephrol 2001;11:6-11.
30. Buranakitjaroen P, Phoocharoenchanachai M, Saravich S. Microalbuminuria in Thai Essential Hypertension Patients. J Int Med Res 2007;35:836-47.
31. Pruijm MT1, Madeleine G, Riesen WF, et al. Prevalence of microalbuminuria in the general population of Seychelles and strong association with diabetes and hypertension independent of renal markers. J Hypertens 2008;26:871-7.
32. Tebbe U, Bramlage P, Thoenes M, et al. Prevalence of microalbuminuria and its associated cardiovascular risk: German and Swiss results of the recent global i-SEARCH survey. Swiss Med Wkly 2009;139:473-80.
33. Gojaseni P, Phaopha A, Chailimpamontree W, et al. Preva- lence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients. Vasc Health Risk Manag 2010;6:157-65.
34. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta- analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.
35. Corrao G , Parodi A, Zambon A, et al. Reduced discon- tinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28:1584-90.
36. Egan BM , Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124-31.